280 related articles for article (PubMed ID: 20664170)
1. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice.
Hanson J; Gille A; Zwykiel S; Lukasova M; Clausen BE; Ahmed K; Tunaru S; Wirth A; Offermanns S
J Clin Invest; 2010 Aug; 120(8):2910-9. PubMed ID: 20664170
[TBL] [Abstract][Full Text] [Related]
2. Role of HCA₂ (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin.
Hanson J; Gille A; Offermanns S
Pharmacol Ther; 2012 Oct; 136(1):1-7. PubMed ID: 22743741
[TBL] [Abstract][Full Text] [Related]
3. Seeing red: flushing out instigators of niacin-associated skin toxicity.
Dunbar RL; Gelfand JM
J Clin Invest; 2010 Aug; 120(8):2651-5. PubMed ID: 20664168
[TBL] [Abstract][Full Text] [Related]
4. Langerhans cells release prostaglandin D2 in response to nicotinic acid.
Maciejewski-Lenoir D; Richman JG; Hakak Y; Gaidarov I; Behan DP; Connolly DT
J Invest Dermatol; 2006 Dec; 126(12):2637-46. PubMed ID: 17008871
[TBL] [Abstract][Full Text] [Related]
5. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.
Benyó Z; Gille A; Kero J; Csiky M; Suchánková MC; Nüsing RM; Moers A; Pfeffer K; Offermanns S
J Clin Invest; 2005 Dec; 115(12):3634-40. PubMed ID: 16322797
[TBL] [Abstract][Full Text] [Related]
6. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells.
Benyó Z; Gille A; Bennett CL; Clausen BE; Offermanns S
Mol Pharmacol; 2006 Dec; 70(6):1844-9. PubMed ID: 17008386
[TBL] [Abstract][Full Text] [Related]
7. beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice.
Walters RW; Shukla AK; Kovacs JJ; Violin JD; DeWire SM; Lam CM; Chen JR; Muehlbauer MJ; Whalen EJ; Lefkowitz RJ
J Clin Invest; 2009 May; 119(5):1312-21. PubMed ID: 19349687
[TBL] [Abstract][Full Text] [Related]
8. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential.
Gaidarov I; Chen X; Anthony T; Maciejewski-Lenoir D; Liaw C; Unett DJ
Cell Signal; 2013 Oct; 25(10):2003-16. PubMed ID: 23770183
[TBL] [Abstract][Full Text] [Related]
9. The niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survival.
Elangovan S; Pathania R; Ramachandran S; Ananth S; Padia RN; Lan L; Singh N; Martin PM; Hawthorn L; Prasad PD; Ganapathy V; Thangaraju M
Cancer Res; 2014 Feb; 74(4):1166-78. PubMed ID: 24371223
[TBL] [Abstract][Full Text] [Related]
10. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid.
Pike NB
J Clin Invest; 2005 Dec; 115(12):3400-3. PubMed ID: 16322787
[TBL] [Abstract][Full Text] [Related]
11. Future of GPR109A agonists in the treatment of dyslipidaemia.
Wanders D; Judd RL
Diabetes Obes Metab; 2011 Aug; 13(8):685-91. PubMed ID: 21418500
[TBL] [Abstract][Full Text] [Related]
12. Structure-guided engineering of biased-agonism in the human niacin receptor via single amino acid substitution.
Yadav MK; Sarma P; Maharana J; Ganguly M; Mishra S; Zaidi N; Dalal A; Singh V; Saha S; Mahajan G; Sharma S; Chami M; Banerjee R; Shukla AK
Nat Commun; 2024 Mar; 15(1):1939. PubMed ID: 38431681
[TBL] [Abstract][Full Text] [Related]
13. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
Kamanna VS; Kashyap ML
Am J Cardiol; 2007 Dec; 100(11 A):S53-61. PubMed ID: 18047854
[TBL] [Abstract][Full Text] [Related]
14. Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis.
Ingersoll MA; Potteaux S; Alvarez D; Hutchison SB; van Rooijen N; Randolph GJ
Immunobiology; 2012 May; 217(5):548-57. PubMed ID: 21798616
[TBL] [Abstract][Full Text] [Related]
15. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.
Lauring B; Taggart AK; Tata JR; Dunbar R; Caro L; Cheng K; Chin J; Colletti SL; Cote J; Khalilieh S; Liu J; Luo WL; Maclean AA; Peterson LB; Polis AB; Sirah W; Wu TJ; Liu X; Jin L; Wu K; Boatman PD; Semple G; Behan DP; Connolly DT; Lai E; Wagner JA; Wright SD; Cuffie C; Mitchel YB; Rader DJ; Paolini JF; Waters MG; Plump A
Sci Transl Med; 2012 Aug; 4(148):148ra115. PubMed ID: 22914621
[TBL] [Abstract][Full Text] [Related]
16. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist.
Tang H; Lu JY; Zheng X; Yang Y; Reagan JD
Biochem Biophys Res Commun; 2008 Oct; 375(4):562-5. PubMed ID: 18722346
[TBL] [Abstract][Full Text] [Related]
17. Nicotinic acid receptor agonists differentially activate downstream effectors.
Richman JG; Kanemitsu-Parks M; Gaidarov I; Cameron JS; Griffin P; Zheng H; Guerra NC; Cham L; Maciejewski-Lenoir D; Behan DP; Boatman D; Chen R; Skinner P; Ornelas P; Waters MG; Wright SD; Semple G; Connolly DT
J Biol Chem; 2007 Jun; 282(25):18028-18036. PubMed ID: 17452318
[TBL] [Abstract][Full Text] [Related]
18. High dietary niacin may increase prostaglandin formation but does not increase tumor formation in ApcMin/+ mice.
Kwong AM; Tippin BL; Materi AM; Buslon VS; French SW; Lin HJ
Nutr Cancer; 2011; 63(6):950-9. PubMed ID: 21774590
[TBL] [Abstract][Full Text] [Related]
19. Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages.
Feingold KR; Moser A; Shigenaga JK; Grunfeld C
J Lipid Res; 2014 Dec; 55(12):2501-8. PubMed ID: 25320346
[TBL] [Abstract][Full Text] [Related]
20. Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes.
Li X; Millar JS; Brownell N; Briand F; Rader DJ
Biochem Pharmacol; 2010 Nov; 80(9):1450-7. PubMed ID: 20655299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
